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INTRODUCTION:  Letrozole,  an  aromatase  inhibitor,  is a commonly  used  neo-adjuvant  drug  to treat
hormone-sensitive  breast  cancer.  There  have  been  a  few  cases  of  aromatase  inhibitor  induced  vasculitis
but  the ﬁrst  case  of letrozole-induced  vasculitis  was  reported  from  Switzerland  in 2014  (Digklia  et  al.)
[1].
PRESENTATION  OF  CASE:  We report  the  case  of  a 72-year-old  woman  with  a small  breast  cancer.  She  was
started  on pre-operative  letrozole  (2.5 mg/d)  whilst  awaiting  surgery.  Ten  days  later  she  presented  with
burning  pain  and  purpuric  skin  lesions  which  progressed  to extensive  ischaemic  superﬁcial  necrosis  of
the lower  limb  skin,  resolving  over  3–4 months  after  local and  systemic  steroids.  Histologically,  it showed
leucocytoclasis  with  evidence  of  eosinophilia  consistent  with  a  diagnosis  of cutaneous  leukocytoclastic
small  vessel  vasculitis.
DISCUSSION:  The  initial  clinical  presentation  was  severe  burning  pain  around  the  ankles  and  a  spreading
violaceous  rash.  Letrozole  was stopped.  Wide  local  excision  (lumpectomy)  and sentinel  node  biopsy  were
postponed  because  of  the accompanying  pneumonitis  and  gastrointestinal  upset,  and  were  carried  out 3.5
months  later.  Fortunately,  the  tumour  size  did not  increase,  but appeared  to  reduce,  and axillary  lymph
nodes  remained  negative,  i.e.,  this  patient’s  cancer  outcome  does  not  seem  to  have  been  jeopardized.
CONCLUSION:  Leukocytoclastic  vasculitis  is  a hypersensitivity  reaction  that  is  usually  self-resolving,
though  our  case  needed  systemic  steroid  treatment.  Letrozole  is  a commonly  used drug  in  clinical  prac-
tice  and  prescribers  should  be aware  of  this  rare side  effect,  which  in  our  case  delayed  treatment  without
any  apparent  harm  and  possibly  reduced  tumour  size.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Aromatase inhibitors have replaced tamoxifen as the preferred
adjuvant endocrine treatment in the majority of postmenopausal
breast cancer patients. They inhibit or inactivate the aromatase
enzyme and therefore inhibit oestrogen synthesis in peripheral fat,
the main source of oestrogen after menopause. Generally, they are
well-tolerated and common side effects include nausea, vomiting,
Abbreviations: PCR, protein creatinine ratio; ANCA, anti-neutrophil cytoplasmic
antibody; CLSVV, cutaneous leukocytoclastic small vessel vasculitis; HE, hema-
toxylin and eosin stain.
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alopecia, dry skin and osteoporosis. Cutaneous manifestations are
rare, with few documented cases of erythema nodosum, cutaneous
vasculitis, toxic epidermal necrolysis, Henoch-Schönlein purpura,
and cutaneous lupus erythematosus [2–8].
A vasculitis secondary to letrozole has been reported in
Switzerland [1] but to the best of our knowledge, this is the only
other case reported in the world.
2. Presentation of case
A 72 year old woman with left-sided invasive lobular carcinoma
of the breast (18 × 8 × 7 mm on ultrasound, Grade 2, ER positive,
PR positive, HER2 negative, Mib-1/Ki67 proliferation index 15%)
was scheduled to have a wide local excision of the cancer (lumpec-
tomy) and sentinel node biopsy. However, due to her wish to visit
http://dx.doi.org/10.1016/j.ijscr.2015.09.024
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Images taken on the ﬁrst day and a week later showing palpable purpura and violaceous macules becoming conﬂuent with superﬁcial skin necrosis: Left 17th Feb
2015,  Right 24th Feb 2015.
her elderly husband in Ireland, the surgery was  postponed and
letrozole was started in the meantime. She was taking amlodip-
ine and bendroﬂumethiazide for hypertension, digoxin and aspirin
for atrial ﬁbrillation, simvastatin, occasionally a salbutamol inhaler
for asthma, and co-codamol for knee pain. She has no known drug
allergies.
A day before the surgery (i.e 14 days after starting letrozole)
the patient gave a four-day history of a severe burning sensation
around both ankles. The overlying skin had an erythematous and
violaceous rash with blisters and was tender on palpation (Fig. 1).
She gave a two-day history of vomiting and diarrhoea as well
as a productive cough and wheeze, but no haematemesis and no
haemoptysis.
Urine dipstick showed mild proteinuria and Protein Creatinine
Ratio (PCR) of 48 (normal range: <45 mg/mmol), but no haema-
turia. Her observations including blood pressure (131/81 mmHg)
were all normal and blood cultures did not show any growth.
Anti-Nuclear Antibody was  negative, Anti-Neutrophil Cytoplasmic
Antibody (ANCA) was negative but complement C4 was raised to
51 mg/dL (normal range: 20–40 mg/dL). A diagnosis of vasculitis,
possibly related to letrozole use, was considered and a skin punch
biopsy of the rash on the right leg was taken (Fig. 1).
Letrozole was stopped and the patient was started on topical
steroid, clobetasol propionate 0.05% (Dermovate). The pneumonitis
and gastrointestinal upset meant that the scheduled lumpectomy
had to be cancelled. Amoxicillin was started.
Five days later there was increased burning sensation around
both ankles and lower legs (Fig 1, right). There was circumferential
necrosis on the right leg and multiple non-exudative violaceous
small lesions extending to both upper thighs and lower back. There
was breakdown of the skin with crusting of coalescent areas. The
right leg was warm to touch and pedal oedema extended to the
mid-shin. She was unable to tolerate clobetasol propionate due to
intense pain when applying it and instead was started on analgesia
and 40 mg  of oral Prednisolone. She was admitted for observation
and pain relief.
By this time, the histopathology of the punch biopsy was avail-
able and showed extensive ischaemic necrosis of the epidermis
and the papillary dermis, with the formation of a sub-epidermal
blister. There was  interstitial haemorrhage with scattered nuclear
dust and karyorrhectic debris (leucocytoclasis). Neutrophils and
eosinophils surrounded the blood vessels and there was inﬁltration
of vessel walls with ﬁbrinoid necrosis, consistent with a diagnosis
of cutaneous leukocytoclastic small vessel vasculitis (Fig. 2).
Renal function improved quickly, ruling out signiﬁcant renal
involvement. Three days later the legs were still painful but the
erythematous area had decreased in size. The following week
there were no new lesions but there was  extensive superﬁcial skin
necrosis. The prednisolone dose was  tapered off. Letrozole was
not re-introduced. The lesions healed over the next 10–12 weeks
(Fig. 3).
Three and a half months after the initial scheduled surgery (17th
February 2015), the patient underwent wire guided wide local exci-
sion of the tumour and sentinel node biopsy on 2nd June 2015.
The ﬁnal pathology report conﬁrmed a 12 mm invasive lobular
carcinoma excised with clear margins. Lymphovascular invasion
was absent and the sentinel lymph node was  free of metastasis.
She received postoperative breast radiotherapy with tumour bed
boost and is currently on tamoxifen (20 mg/d), a selective oestro-
gen receptor modulator (SERM), rather than an aromatase inhibitor
for adjuvant systemic therapy.
3. Discussion
Leukocytoclastic vasculitis is an immune complex-mediated
reactive transient small-vessel vasculitis. It causes 10–20% of all
small-vessel vasculitides [9]. Cutaneous leukocytoclastic small ves-
sel vasculitis (CLSVV) is a diagnosis of exclusion, and infection and
Fig. 2. Left HE; ×100 magniﬁcation: Necrotic epidermis lies partly detached from the underlying dermis to form a subepidermal blister. Right HE; ×200 magniﬁcation:
Dermal changes of ﬁbrinoid necrosis involving small vessels, karyorrhectic debris (leucocytoclasis) and red blood cell extravasation.
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Fig. 3. The lesions at 1 month top left (18th March 2015), 6 weeks top right (30th March 2015), 12 weeks middle left (11th May  2015), 14 weeks middle right (20th May
2015),  and 18 weeks bottom left and bottom right (both 15th June 2015).
connective tissue disease need to be ruled out by negative ANCA
levels and through biopsy. Over 100 drugs have been known to
cause either CLSVV or drug-induced lupus, though the absolute
frequency of drug-induced vasculitis is approximately 1/100,000
people [10,11].
The pathogenesis of aromatase inhibitor induced vasculitis is
not fully understood. It is thought that higher circulating oestro-
gen levels inhibit neutrophil function. Therefore, the reduction of
oestrogen due to aromatase inhibition could increase neutrophil
activity. This would account for the high levels of neutrophils seen
in the biopsy. Neutrophils adhere to the blood vessel endothe-
lium, resulting in autoimmunity [12]. Similar case reports have
also postulated that the down-regulation of oestrogen could in fact
directly induce vasculitis [4,6]. A similar vasculitic reaction around
the ankles occurred in a patient after commencing letrozole in
Switzerland in 2014 [1]. As this is a hypersensitivity reaction, not
an allergy, we do not believe that the preservatives or excipients
could be implicated.
It is important to think about vasculitis as a spectrum. Although
often asymptomatic, patients can present with non-speciﬁc symp-
toms such as fever and malaise, cutaneous symptoms such as
localised pain, pruritus and palpable purpura, or multi-organ failure
affecting the kidney and the lung [13]. Skin lesions arise in clusters
and commonly affect the lower legs and ankles [14].
The CLSVV in this patient was  histologically characterised by
three main features. Firstly, karyorrhexis of neutrophil nuclei,
also known as leucocytoclasis. Secondly, vascular damage from
the leukocytoclastic granules and ﬁbrinoid necrosis. Thirdly, the
presence of tissue eosinophilia. Though tissue eosinophilia is not
speciﬁc for CLSVV, Bahrami et al. found that it was signiﬁcantly
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more common in drug-induced CLSVV compared to small-vessel
vasculitides not caused by drugs [15].
CLSVV is a transient vasculitis and usually self-limiting. As such,
treatment is often unnecessary. The drug causing the reaction needs
to be removed; and stasis needs to be minimised by compression,
elevation and the use of non-steroidal anti-inﬂammatory drugs.
Anti-histamines and systemic corticosteroids may  need to be pre-
scribed, particularly when the cutaneous lesions are progressive,
as in our case. Up to 10% of patients could suffer from recurrent
disease.
It is possible that the CLSVV was unrelated to letrozole. It
might have been related to the pneumonitis, rather than the
other way round. It is unlikely to have been a paraneoplastic
phenomenon [14,16] because the vasculitis improved while the
tumour remained in situ and the tumour may  have reduced in size
(as discussed below).
It is interesting that the ﬁnal histological tumour size was
smaller (12 mm)  than the initial tumour size seen on imaging
(15 mm on mammography, 18 mm on ultrasound and 21 mm on
MRI); the patient had taken letrozole for less than 2 weeks fol-
lowed by nearly 4 months of no speciﬁc treatment for the cancer.
Although we do not have tumour size measurement when the drug
was stopped, it is unlikely to have reduced so dramatically, so one
could speculate that the immune reaction leading to the vasculitis
might have had a tumour suppressive effect.
4. Conclusion
In conclusion, we report the second case worldwide of CLSVV
very likely to be secondary to letrozole treatment. In all patients
with this presentation, it is important to exclude systemic primary
vasculitides, which would require treatment with immunosup-
pressant therapy. CLSVV is a transient hypersensitivity reaction
with good prognosis. The suspected offending drug needs to be
discontinued and symptomatic treatment should be given and
may  need to be supplemented with local and systemic steroids.
Although exceptionally rare and not life threatening, it is important
to keep in mind this alarming side effect of letrozole, particularly
because it is a commonly used drug in breast cancer treatment. It
is interesting that the cancer did not appear to grow during the 4
months of ‘no-treatment’ after the initial 10–12 days of letrozole
treatment and may  have even shrunk.
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